Dennis Kim, MD, PhD.
Oncologist/Hematologist
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre

Allogeneic hematopoietic stem cell transplantation is still a potential therapeutic option for myeloma although it is nowadays used very rarely in the clinic. However, multiple studies suggested that graftversusmyeloma effect could potentially eradicate myeloma clones following allogeneic hematopoietic stem cell transplantation.

In this presentation, we will discuss overview of the principle of allogeneic hematopoietic stem cell transplantation, current trend of its usage as well as posttransplant complications, particularly on the graftversushost disease and its pathogenesis, clinical presentation and its management. Also, we will discuss shortly about the contemporary indication of allogeneic transplantation for myeloma treatment.